- $3.25bn
- $2.94bn
- $460.16m
Brief: Zai Lab Announces Strategic Partnership And Global License Agreement With Medilink Therapeutics For A Next Generation Antibody-Drug Conjugate Program In Oncology
Brief: Zai Lab Ltd Posts FY Net Loss Attributable Of $443.3 Mln
Karuna Therapeutics rebounds after $400 mln equity raise
Karuna Therapeutics slides after $400 mln stock offering launch
Karuna's schizophrenia drug meets main goal in late-stage trial (updated)
Karuna's schizophrenia drug meets main goal in late-stage trial
U.S. RESEARCH ROUNDUP-Adobe, Five Below, Lennar
Over a dozen Chinese-based firms say they have minimal exposure to SVB (updated)
Brief: Zai Lab Announces Amount Held At Silicon Valley Bank Immaterial
Brief: Zai Lab Announces Full-Year 2022 Financial Results And Recent Corporate Updates
Brief: Zai Lab Reports NDA Acceptance Of Sulbactam-Durlobactam (SUL-DUR) For Infections Caused By Acinetobacter Baumannii In China By NMPA
Brief: Zai Lab Announces NDA For Sulbactam-Durlobactam Granted Priority Review By China's NMPA
Brief: FMR LLC's Long Position In Ordinary Shares Of Zai Lab Rises To 9.26% - HKEX Filing
Brief: Zai Lab Announces Inclusion Of QINLOCK and NUZYRA In China’s National Reimbursement Drug List
Zai Lab's HK shares post record jump on positive data from partner's cancer therapy
U.S. STOCKS ON THE MOVE-Lamb Weston Foldings, Stitch Fix, Bellerophon Therapeutics
U.S. STOCKS ON THE MOVE-Boxed Inc, Oil companies, Tesla
Zai Lab soars on positive data from partner's cancer therapy
Brief: Zai Lab, Novocure Announces Pivotal Lunar Study